TELA Bio, Inc. (TELA) Insider Trading Activity

NASDAQ$1.18
Market Cap
$47.57M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
74 of 823
Rank in Industry
4 of 108

TELA Insider Trading Activity

TELA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$4,000,440
1
100
Sells
$0
0
0

Related Transactions

EW HEALTHCARE PARTNERS FUND 2, L.P.See Remarks
1
$4M
0
$0
$4M

About TELA Bio, Inc.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Insider Activity of TELA Bio, Inc.

Over the last 12 months, insiders at TELA Bio, Inc. have bought $4M and sold $0 worth of TELA Bio, Inc. stock.

On average, over the past 5 years, insiders at TELA Bio, Inc. have bought $7.64M and sold $1.91M worth of stock each year.

Highest buying activity among insiders over the last 12 months: EW HEALTHCARE PARTNERS FUND 2, L.P. (See Remarks) — $4M.

The last purchase of 3,604,000 shares for transaction amount of $4M was made by EW HEALTHCARE PARTNERS FUND 2, L.P. (See Remarks) on 2025‑11‑17.

List of Insider Buy and Sell Transactions, TELA Bio, Inc.

2025-11-17PurchaseEW HEALTHCARE PARTNERS FUND 2, L.P.See Remarks
3.6M
8.8578%
$1.11
$4M
0.00%
2024-10-24PurchaseKOBLISH ANTONYChief Executive Officer
88,888
0.325%
$2.25
$199,998
-26.55%
2024-10-24PurchaseCuca RobertoCOO and CFO
64,444
0.2356%
$2.25
$144,999
-26.55%
2024-10-24PurchaseTalmo PaulChief Technology Officer
22,222
0.0813%
$2.25
$50,000
-26.55%
2024-10-24PurchaseFirestone Gregory A.Chief Commercial Officer
6,666
0.0244%
$2.25
$14,999
-26.55%
2024-07-02SaleORBIMED ADVISORS LLC10 percent owner
36,600
0.1299%
$4.54
$166,164
-42.52%
2024-07-01SaleORBIMED ADVISORS LLC10 percent owner
13,700
0.0501%
$4.68
$64,116
-40.98%
2024-06-28SaleORBIMED ADVISORS LLC10 percent owner
378,000
1.4002%
$4.74
$1.79M
-43.62%
2023-12-05PurchaseFirestone Gregory A.Chief Business Officer
2,600
0.011%
$5.65
$14,688
-9.72%
2023-11-14PurchaseKOBLISH ANTONYChief Executive Officer
11,000
0.0454%
$4.54
$49,976
+9.47%
2023-11-14PurchaseCuca RobertoCOO and CFO
10,000
0.0408%
$4.49
$44,938
+9.47%
2023-04-21SaleORBIMED ADVISORS LLC10 percent owner
27,700
0.1432%
$9.41
$260,657
-24.76%
2023-04-20SaleORBIMED ADVISORS LLC10 percent owner
28,300
0.1502%
$9.43
$266,869
-22.68%
2023-04-19SaleORBIMED ADVISORS LLC10 percent owner
136,000
0.7142%
$9.30
$1.26M
-22.32%
2022-11-03PurchaseOpaleye Management Inc.director
20,262
0.1236%
$7.81
$158,285
+26.43%
2022-10-11PurchaseOpaleye Management Inc.director
16,000
0.0971%
$8.00
$128,000
+22.84%
2022-08-17PurchaseEW Healthcare Partners Fund 2-UGP, LLC
500,000
2.8654%
$8.00
$4M
+19.45%
2022-08-16PurchaseOpaleye Management Inc.
15,000
0.0881%
$8.00
$120,000
+22.39%
2022-08-10PurchaseOpaleye Management Inc.
11,500
0.0684%
$8.52
$98,006
+16.37%
2022-08-01PurchaseOpaleye Management Inc.10 percent owner
4,979
0.0296%
$7.96
$39,632
+24.38%
Total: 178
*Gray background shows transactions not older than one year

Insider Historical Profitability

4.19%
EW HEALTHCARE PARTNERS FUND 2, L.P.See Remarks
7714709
19.1355%
$9.1M1180
+1.91%
EW Healthcare Partners Fund 2-UGP, LLC
4105709
10.1838%
$4.84M250
+12.99%
ORBIMED ADVISORS LLC10 percent owner
2407242
5.9709%
$2.84M16
+2.92%
Opaleye Management Inc.director
1948000
4.8318%
$2.3M100
+27.85%
RTW INVESTMENTS, LP10 percent owner
1139358
2.8261%
$1.34M11
+23.06%
Oliva Adele C
888664
2.2042%
$1.05M10
+2.92%
Quaker BioVentures II LP10 percent owner
888664
2.2042%
$1.05M10
+2.92%
KOBLISH ANTONYChief Executive Officer
458897
1.1382%
$541,498.4620
<0.0001%
Zuga Mattdirector
260808
0.6469%
$307,753.4410
+2.92%
Azarbarzin Kurtdirector
260808
0.6469%
$307,753.4410
+2.92%
Cuca RobertoCOO and CFO
155388
0.3854%
$183,357.8470
<0.0001%
Talmo PaulChief Technology Officer
91082
0.2259%
$107,476.7610
<0.0001%
Firestone Gregory A.Chief Commercial Officer
57279
0.1421%
$67,589.2220
<0.0001%
*Gray background shows insiders who have made transactions during last year

TELA Institutional Investors: Active Positions

Increased Positions11+20.75%561,497+2.39%
Decreased Positions17-32.08%473,929-2.02%
New Positions<1New35,281New
Sold Out Positions7Sold Out132,417Sold Out
Total Postitions47-11.32%24M+0.37%

TELA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Nantahala Capital Management, Llc$5,878.0011.36%5.11M00%2025-09-30
Essex Woodlands Management, Inc.$4,727.009.14%4.11M00%2025-09-30
Silverarc Capital Management, Llc$3,200.006.18%2.78M+3,128+0.11%2025-09-30
Stonepine Capital Management, Llc$2,479.004.79%2.16M+71,757+3.44%2025-09-30
Vanguard Group Inc$2,070.004%1.8M-111,694-5.84%2025-09-30
Dafna Capital Management Llc$1,657.003.2%1.44M00%2025-09-30
Perkins Capital Management Inc$959.001.85%833,928-41,937-4.79%2025-09-30
Citigroup Inc$863.001.67%750,00000%2025-09-30
Velan Capital Investment Management Lp$860.001.66%747,41000%2025-09-30
Pentwater Capital Management Lp$834.001.61%724,856-90,144-11.06%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.